Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients
- PMID: 7831423
- DOI: 10.1007/BF02251285
Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients
Abstract
Bidirectional drug interactions between fluvoxamine and classical antidepressants were studied in depressed patients. A column switching technique combined with high performance liquid chromatography (HPLC) enabled automated analyses of plasma for simultaneous determination of fluvoxamine, tricyclic and tetracyclic antidepressants and demethylated and major hydroxylated metabolites in a single HPLC run. The measurements revealed that fluvoxamine inhibited N-demethylation of imipramine, clomipramine, amitriptyline and maprotiline whereas interferences with hydroxylation reactions were restricted to aromatic 8-hydroxylation of clomipramine. In patients under fluvoxamine monotherapy before comedication, plasma concentrations of fluvoxamine increased after administration of a tricyclic antidepressant, thus indicating bidirectional drug interactions. The inhibitory effects of fluvoxamine on the metabolism of classical antidepressants disappeared after discontinuation of concomitant fluvoxamine treatment within at least 1-2 weeks. The reported alterations in drug metabolism observed in depressed patients who were under fluvoxamine/tricyclic antidepressant comedication suggested that careful supervision and regular drug monitoring are necessary in such patients.
Similar articles
-
Non-competitive inhibition of clomipramine N-demethylation by fluvoxamine.Psychopharmacology (Berl). 1995 Jan;117(2):149-53. doi: 10.1007/BF02245180. Psychopharmacology (Berl). 1995. PMID: 7753960
-
Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.J Clin Psychiatry. 1996 Jun;57(6):257-64. J Clin Psychiatry. 1996. PMID: 8666564 Clinical Trial.
-
Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data.Clin Pharmacokinet. 1990 Sep;19(3):241-55. doi: 10.2165/00003088-199019030-00007. Clin Pharmacokinet. 1990. PMID: 2394063
-
Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.Drugs. 1986 Oct;32(4):313-34. doi: 10.2165/00003495-198632040-00002. Drugs. 1986. PMID: 3096686 Review.
-
Tianeptine: a review of its use in depressive disorders.CNS Drugs. 2001;15(3):231-59. doi: 10.2165/00023210-200115030-00006. CNS Drugs. 2001. PMID: 11463130 Review.
Cited by
-
How important are gender differences in pharmacokinetics?Clin Pharmacokinet. 2002;41(5):329-42. doi: 10.2165/00003088-200241050-00002. Clin Pharmacokinet. 2002. PMID: 12036391 Review.
-
The Role of Metabolites of Antidepressants in the Treatment of Depression.CNS Drugs. 1997 Apr;7(4):273-312. doi: 10.2165/00023210-199707040-00003. CNS Drugs. 1997. PMID: 27520753 Review.
-
The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):287-93. doi: 10.1007/s00406-006-0663-5. Eur Arch Psychiatry Clin Neurosci. 2006. PMID: 16783493 Review.
-
Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.Clin Pharmacokinet. 1997;32 Suppl 1:1-21. doi: 10.2165/00003088-199700321-00003. Clin Pharmacokinet. 1997. PMID: 9068931 Review.
-
Clinically significant drug interactions with antidepressants in the elderly.Drugs Aging. 2002;19(4):299-320. doi: 10.2165/00002512-200219040-00004. Drugs Aging. 2002. PMID: 12038880 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical